United Therapeutics (NASDAQ:UTHR) CEO Sells $4,914,160.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total value of $4,914,160.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,827,875.04. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Trading Down 2.4%

Shares of NASDAQ UTHR opened at $515.46 on Friday. The business has a 50-day moving average of $530.46 and a 200-day moving average of $538.70. The firm has a market capitalization of $22.11 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $303.08 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period last year, the firm posted $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Callan Family Office LLC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $1,217,000. Leuthold Group LLC grew its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG grew its stake in shares of United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP increased its position in United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares in the last quarter. Finally, M&T Bank Corp increased its position in United Therapeutics by 171.6% during the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after buying an additional 1,985 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.